India to Nepal: Adalimumab Export Trade Route
India has recorded 29 verified shipments of Adalimumab exported to Nepal, representing a combined trade value of $130.3K USD. This corridor is served by 6 active Indian exporters, with an average shipment value of $4.5K USD. The leading Indian exporter is ZYDUS LIFESCIENCES LIMITED, which accounts for 42% of total export value with 15 shipments worth $55.4K USD. On the buying side, D. K. M. PHARMACEUTICALS PVT. LTD. is the largest importer in Nepal with $38.4K USD in purchases. The top 3 suppliers — ZYDUS LIFESCIENCES LIMITED, CADILA HEALTHCARE LIMITED, RELIANCE LIFE SCIENCES PRIVATE LIMITED — together control 86% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to Nepal Adalimumab corridor is one of India's established pharmaceutical export routes, with 29 shipments documented worth a combined $130.3K USD. The route is dominated by ZYDUS LIFESCIENCES LIMITED, which alone accounts for roughly 42% of all export value, reflecting the consolidated nature of India's adalimumab manufacturing sector.
Across 6 active suppliers, the average shipment value stands at $4.5K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 70% of all shipments, consistent with adalimumab's non-urgent bulk-order profile.
Shipment activity peaks during July–September, with an average transit time of 24 days port-to-port. The route has recorded an annual growth rate of 30.1%, placing it at rank #9 among India's top adalimumab export destinations globally.
On the import side, key buyers of Indian adalimumab in Nepal include D. K. M. PHARMACEUTICALS PVT. LTD., D K M PHARMACEUTICALS PRIVATE LIMITED, D K M PHARMACEUTICALS PVT LTD and 4 others. D. K. M. PHARMACEUTICALS PVT. LTD. is the single largest importer with 12 shipments valued at $38.4K USD.
